Poster Ref News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile

Sangamo Therapeutics Announces Updated Phase 1/2 STAAR Study Data in Fabry Disease Showing Sustained Benefit and Differentiated Safety Profile
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

San diegoUnited statesLouise wilkieLisa rojkjaerRobert hopkinFabry outcomeExchange commissionEuropean medicines agencySangamo therapeutics incDrug administrationCincinnati children hospital medical centerClinical applicationsPoster refCincinnati childrenHospital medical centerChief medical officer

Sangamo Therapeutics (SGMO) Announces Updated Phase 1/2 STAAR Study Data

Sangamo Therapeutics (SGMO) Announces Updated Phase 1/2 STAAR Study Data
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSan diegoRobert hopkinLisa rojkjaerFabry outcomeCincinnati children hospital medical centerSangamo therapeutics incSangamo therapeuticsClinical applicationsPoster refCincinnati childrenHospital medical centerChief medical officerFabry outcome surveyMainz severity score indexGeneral health

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesSandy macraeLouise wilkieCalifornia institute for regenerative medicineHealth care conferenceSangamo therapeutics incExchange commissionAmerican society of hematologyWebcast scheduledChief executive officerZinc fingerQuarter updatesRecent businessTransplant rejectionAmerican societyFull year

Sangamo Therapeutics, Inc : Sangamo Therapeutics Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease

Sustained, elevated expression of alpha-galactosidase A (a-Gal A) activity observed in 13 patients for over two years for the longest treated patient as of cutoff date. Achieved 78% globotriaosylceramide

United statesDennis riedlRobert hopkinNathalie dubois stringfellowLouise wilkieDevelopment officerHealth scoresDrug administrationSangamo therapeutics incExchange commissionEuropean medicines agencyCincinnati children hospital medical centerHealth scoreEastern timePoster refCincinnati children

Sangamo Therapeutics (SGMO) Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease

Sangamo Therapeutics (SGMO) Announces Evidence of Clinical Benefit in Phase 1/2 STAAR Study in Fabry Disease
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRobert hopkinNathalie dubois stringfellowHealth scoresDevelopment officerCincinnati children hospital medical centerHealth scoreSangamo therapeutics incWall streetEastern timePoster refCincinnati childrenHospital medical centerGeneral health scoresGeneral health scoreSenior vice president